Upregulation of M3 muscarinic receptor inhibits cardiac hypertrophy induced by angiotensin II

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Liu, Yan ^a   Wang, Shu ^a,b   Wang, Chao ^a   Song, Haoxin ^a   Han, Hongmei ^a   Hang, Pengzhou ^a   Jiang, Yanan ^a   Wei, Lanlan ^c   Huo, Rong ^a   Sun, Lihua ^a   Gao, Xu ^a   Lu, Yanjie ^a   Du, Zhimin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c Department of Microbiology ^*  (China)

Author keywords

Angiotensin II; Cardiac hypertrophy; Choline; M3 muscarinic acetylcholine receptor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ISOPRENALINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MUSCARINIC M3 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEART RATE; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MEAN ARTERIAL PRESSURE; MOLECULAR PATHOLOGY; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CARDIOMEGALY; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME ACTIVATION; HEART RATE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MYOCARDIUM; ORGAN SPECIFICITY; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, MUSCARINIC M3; UP-REGULATION;

EID: 84883736921     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-209     Document Type: Article

References (30)

1. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target?. Circulation 2004, 109:1580-1589. 10.1161/01.CIR.0000120390.68287.BB, 15066961.
2. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signaling pathways. Nat Rev Mol Cell Biol 2006, 7:589-600.
3. Gilsbach R, Schneider J, Lother A, Schickinger S, Leemhuis J, Hein L. Sympathetic α2 -adrenoceptors prevent cardiac hypertrophy and fibrosis in mice at baseline but not after chronic pressure overload. Cardiovasc Res 2010, 86:432-442. 10.1093/cvr/cvq014, 20083574.
4. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J 2007, 28:989-995. 10.1093/eurheartj/ehm048, 17409109.
5. Ohshima S, Isobe S, Izawa H, Nanasato M, Ando A, Yamada A, Yamada K, Kato TS, Obata K, Noda A, Nishizawa T, Kato K, Nagata K, Okumura K, Murohara T, Yokota M. Cardiac sympathetic dysfunction correlates with abnormal myocardial contractile reserve in dilated cardiomyopathy patients. J Am Coll Cardiol 2005, 46:2061-2068. 10.1016/j.jacc.2005.08.046, 16325043.
6. Shi H, Wang HZ, Wang ZG. Identification and characterization of multiple subtypes of muscarinic acetylcholine receptors and their physiological functions in canine hearts. Mol Pharmacol 1999, 55:497-507.
7. Wang HZ, Shi H, Lu YJ, Yang BF, Wang ZG. Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K+ current. Br J Pharmacol 1999, 126:1725-1734. 10.1038/sj.bjp.0702486, 1565960, 10372814.
8. Wang ZG, Shi H, Wang HZ. Functional M3 muscarinic acetylcholine receptors in mammalian hearts. Br J Pharmacol 2004, 142:395-408. 10.1038/sj.bjp.0705787, 1574958, 15148264.
9. Liu Y, Sun HL, Li DL, Wang LY, Gao Y, Wang YP, Du ZM, Lu YJ, Yang BF. Choline produces antiarrhythmic actions in animal models by cardiac M3 receptors: improvement of intracellular Ca2+ handling as a common mechanism. Can J Physiol Pharmacol 2008, 86:860-865. 10.1139/Y08-094, 19088807.
10. Wang S, Han HM, Jiang YN, Wang C, Song HX, Pan ZY, Fan K, Du J, Fan YH, Du ZM, Liu Y. Activation of cardiac M3 muscarinic acetylcholinereceptors has cardioprotective effects against ischaemia-induced arrhythmias. Clin Exp Pharmacol Physiol 2012, 39:343-349. 10.1111/j.1440-1681.2012.05672.x, 22224440.
11. Liu Y, Du J, Gao Y, Zhang Y, Cai BZ, Zhao H, Qi HP, Du ZM, Lu YJ, Yang BF. Role of M3 receptor in aconitine/barium-chloride-induced preconditioning against arrhythmias in rats. Naunyn Schmiedebergs Arch Pharmacol 2009, 379:511-515. 10.1007/s00210-008-0376-6, 19043693.
12. Liu Y, Wang Y, Ma ML, Zhang Y, Li HW, Chen QW, Yang BF. Cardiac hemodynamic effects of M3 receptor agonist on rat and rabbit hearts. Yao Xue Xue Bao 2001, 36:84-87.
13. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008, 372:817-821. 10.1016/S0140-6736(08)61171-X, 18757091.
14. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in postmyocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007, 28:3012-3019. 10.1093/eurheartj/ehm489, 17981830.
15. Lamping KG, Wess J, Cui Y, Nuno DW, Faraci FM. Muscarinic (M) receptors in coronary circulation: gene-targeted mice define the role of M2 and M3 receptors in response to acetylcholine. Arterioscler Thromb Vasc Biol 2004, 24:1253-1258. 10.1161/01.ATV.0000130661.82773.ca, 15130910.
16. Zhao QY, Huang CX, Jiang H, Okello E, Tang YH, Wang ZW, Wu ZY. M2 and M3-muscarinic acetylcholine receptors remodeling in patients with a dilated atrium. Acta Cardiol 2008, 63:166-170. 10.2143/AC.63.2.2029523, 18468195.
17. Liu Y, Sun LH, Pan ZW, Bai YL, Wang N, Zhao JL, Xu CQ, Li Z, Li BX, Du ZM, Lu YJ, Gao X, Yang BF. Over-expression of M3 muscarinic receptor is a novel strategy for preventing sudden cardiac death in transgenic mice. Mol Med 2011, 17:1179-1187. 3321805, 21785809.
18. Frank D, Kuhn C, van Eickels M, Gehring D, Hanselmann C, Lippl S, Will R, Katus HA, Frey N. Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy. Circulation 2007, 116:2587-2596. 10.1161/CIRCULATIONAHA.107.711317, 18025526.
19. Rottman JN, Ni G, Khoo M, Wang Z, Zhang W, Anderson ME, Madu EC. Temporal changes in ventricular function assessed echocardiographically in conscious and anesthetized mice. J Am Soc Echocardiogr 2003, 16:1150-1157. 10.1067/S0894-7317(03)00471-1, 14608286.
20. Grote-Wessels S, Baba HA, Boknik P, El-Armouche A, Fabritz L, Gillmann HJ, Kucerova D, Matus M, Müller FU, Neumann J, Schmitz M, Stümpel F, Theilmeier G, Wohlschlaeger J, Schmitz W, Kirchhefer U. Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload. Cardiovasc Res 2008, 79:464-471. 10.1093/cvr/cvn113, 18453636.
21. Kwak BR, van Kempen MJ, Théveniau-Ruissy M, Gros DB, Jongsma HJ. Connexin expression in cultured neonatal rat myocytes reflects the pattern of the intact ventricle. Cardiovasc Res 1999, 44:370-380. 10.1016/S0008-6363(99)00196-0, 10690313.
22. Tomita H, Nazmy M, Kajimoto K, Yehia G, Molina CA, Sadoshima J. Inducible cAMP early repressor (ICER) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to β-adrenergic receptor stimulation. Circ Res 2003, 93:12-22. 10.1161/01.RES.0000079794.57578.F1, 12791704.
23. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003, 41:2164-2171. 10.1016/S0735-1097(03)00471-6, 12821241.
24. Liu JJ, Li DL, Zhou J, Sun L, Zhao M, Kong SS, Wang YH, Yu XJ, Zhou J, Zang WJ. Acetylcholine prevents angiotensin II-induced oxidative stress and apoptosis in H9c2 cells. Apoptosis 2011, 16:94-103. 10.1007/s10495-010-0549-x, 20963497.
25. Pellieux C, Sauthier T, Aubert JF, Brunner HR, Pedrazzini T. Angiotensin II induced cardiac hypertrophy is associated with different mitogen-activated protein kinase activation in normotensive and hypertensive mice. J Hypertens 2000, 18:1307-1317. 10.1097/00004872-200018090-00017, 10994762.
26. Bao W, Behm DJ, Nerurkar SS, Ao Z, Bentley R, Mirabile RC, Johns DG, Woods TN, Doe CP, Coatney RW, Ohlstein JF, Douglas SA, Willette RN, Yue TL. Effects of p38 MAPK inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 2007, 49:362-368. 10.1097/FJC.0b013e318046f34a, 17577100.
27. Shi H, Wang H, Li D, Nattel S, Wang Z. Differential alterations of receptor densities of three muscarinic acetylcholine receptor subtypes and current densities of the corresponding K+ channels in canine atria with atrial fibrillation induced by experimental congestive heart failure. Cell Physiol Biochem 2004, 14:31-40. 10.1159/000076924, 14976404.
28. Zhai PY, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle E, Yu X, Kupershmidt S, Roden DM, Wagner T, Yatani A, Vatner DE, Vatner SF, Sadoshima J. Cardiac-specific overexpression of AT1 receptor mutant lacking Gq/Gi coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005, 115:3045-3056. 10.1172/JCI25330, 1265872, 16276415.
29. Park JK, Fischer R, Dechend R, Shagdarsuren E, Gapeljuk A, Wellner M, Meiners S, Gratze P, Al-Saadi N, Feldt S, Fiebeler A, Madwed JB, Schirdewan A, Haller H, Luft FC, Muller DN. p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension 2007, 49:481-489. 10.1161/01.HYP.0000256831.33459.ea, 17224470.
30. Luo J, Busillo JM, Benovic JL. M3 muscarinic acetylcholine receptor-mediated signaling is regulated by distinct mechanisms. Mol Pharmacol 2008, 74:338-347. 10.1124/mol.107.044750, 18388243.